Thursday, August 27, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 26, 2026

22nd Century Group Reports Fourth Quarter and Full Year 2025 Financial Results

View original at globenewswire.com
“Ended the calendar year 2025 with cash of $7.1 million.”
Verbatim excerpt from the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Decades of independent clinical research and peer-reviewed studies demonstrated that reducing nicotine content can decrease nicotine intake, increase quit attempts, and reduce overall exposure to nicotine

    60% confidence
  • Additional expansion of new natural style cigarette products launched in 2025 will continue to accelerate revenue and margin growth in the cigarette category

    60% confidence
  • Our strategy and business model now enable tobacco companies of any size to adopt a Partner VLN or licensing pathway with speed and scalability, creating a viable model for the industry to broaden the reach of VLN products

    60% confidence
  • We made important progress in 2025 to strengthen our financial position, exiting the year debt-free with sufficient capital to support near-term growth objectives

    60% confidence
  • During 2025, we executed a strategic pivot toward higher-margin branded products, expanded partnerships with established retail chains, and developed a new tobacco harm reduction category

    60% confidence
  • We eliminated over $8.0 million of legacy debt through repayment, settlement, and exchange during 2025

    60% confidence
  • VLN cigarettes have 95% less nicotine compared to traditional cigarettes and have been proven to allow consumers to greatly reduce their nicotine consumption

    60% confidence
  • Our priorities include expanding VLN retail distribution and consumer awareness, scaling toward profitability, and maintaining active engagement with FDA regulators and public health stakeholders both domestically and internationally

    60% confidence
  • Full rollout of Pinnacle VLN across all remaining store locations is expected in next 90 days supported by in-store marketing materials and digital promotion programs

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com